Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab for Moderate to Severe Genital or Scalp Psoriasis
NCT05969223Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2023
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of risankizumab in genital psoriasis, psoriasis, sponsored by AbbVie Inc.. Started Aug 2023; status: completed.
02
Drugs
risankizumab
03
Conditions
genital psoriasispsoriasis
Beyond the preview
Go deeper on NCT05969223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05969223.